Author Archives: Jose Marques Lopes PhD

Tegsedi Found to Improve Neuropathy Symptoms, Quality of Life in FAP Patients in Phase 3 Trial

Treatment with the investigative therapy Tegsedi (inotersen) provides early and significant improvements in neuropathy symptoms and quality of life in patients with familial amyloid polyneuropathy (FAP), according to results from a pivotal Phase 2/3 clinical trial. These results, announced by Ionis Pharmaceuticals, the treatment’s developer, and its affiliate, Akcea…

Protein Interaction and Aggregation Studies May Provide Key Data for Treatment of Amyloid Diseases, Study Says

Studying the interaction between different amyloid (abnormal disease-causing) proteins may provide insight into the treatment of diseases such as familial amyloid polyneuropathy (FAP), an Indian study suggests. The study, “Q-Rich Yeast Prion [PSI+] Accelerates Aggregation of Transthyretin, a Non-Q-Rich Human Protein,” appeared in the journal Frontiers in…